Neogenomics (NEO) Revenue (2010 - 2026)

Neogenomics has reported Revenue for 17 years, with the latest figure at $186.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 11.09% year-over-year to $186.7 million; the trailing twelve-month figure through Mar 2026 stood at $746.0 million (up 10.95% YoY), and the FY2025 full-year result was $727.3 million, up 10.11% from the prior year.
• Revenue for Q1 2026 stood at $186.7 million, down from $190.2 million in the prior quarter.
• The five-year high for Revenue was $190.2 million in Q4 2025, with the low at $117.2 million in Q1 2022.
• Historically, Revenue has averaged $157.4 million across 5 years, with a median of $156.2 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue increased 1.42% — and 2023, when it increased 17.99%.
• Neogenomics' Revenue stood at $138.7 million in 2022, then climbed by 12.15% to $155.6 million in 2023, then grew by 10.57% to $172.0 million in 2024, then gained by 10.56% to $190.2 million in 2025, then retreated by 1.84% to $186.7 million in 2026.
• The last three Revenue figures came in at $186.7 million (Q1 2026), $190.2 million (Q4 2025), and $187.8 million (Q3 2025), per Business Quant data.